Recombinant Human PCSK9(Gln31-Gln692(Val474Ile,Gly670Glu)) Protein, C-Avi-tagged, Biotinylated
Cat.No. : | PCSK9-353H |
Product Overview : | Recombinant Human PCSK9(Q8NBP7)(Gln31-Gln692(Val474Ile,Gly670Glu)) Protein, fused with a Avi tag at the C-terminus, was produced in HEK293. The purified protein was biotinylated in vitro. |
- Specification
- Gene Information
- Related Products
- Download
Source : | HEK293 |
Species : | Human |
Tag : | Avi |
Form : | Supplied as a 0.2 μm filtered solution of 50mM HEPES,150mM NaCl,20% Glycerol, pH 7.4. |
Molecular Mass : | The recombinant Human PCSK9 Protein has a predicted molecular mass of 14&59kDa, it migrates with an apparent molecular mass of 19&65kDa under reducing conditions. |
AA Sequence : | Gln31-Gln692(Val474Ile,Gly670Glu) |
Endotoxin : | < 0.01 EU per μg of the protein as determined by the LAL method. |
Purity : | Greater than 95% as determined by reducing SDS-PAGE. |
Characteristic : | The biotin to protein ratio is 0.5-1 as determined by the HABA assay. |
Storage : | Samples are stable for up to twelve months from date of receipt at -20°C to -80°C. Store it under sterile conditions at -20°C to -80°C. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles. |
Concentration : | Please refer to the COA for detailed information. |
Shipping : | In general, recombinant proteins are provided as lyophilized powder which are shipped at ambient temperature. Bulk packages of recombinant proteins are provided as frozen liquid. They are shipped out with blue ice unless customers require otherwise. |
Protein length : | Gln31-Gln692 |
Gene Name : | PCSK9 proprotein convertase subtilisin/kexin type 9 [ Homo sapiens ] |
Official Symbol : | PCSK9 |
Synonyms : | PCSK9; proprotein convertase subtilisin/kexin type 9; HCHOLA3, hypercholesterolemia, autosomal dominant 3; FH3; NARC 1; NARC1; NARC-1; HCHOLA3; |
Gene ID : | 353175 |
MIM : | 607786 |
UniProt ID : | Q8NBP7 |
Products Types
◆ Recombinant Protein | ||
PCSK9-035H | Recombinant Human PCSK9 Protein, MYC/DDK-tagged, C13 and N15-labeled | +Inquiry |
PCSK9-312H | Recombinant Human PCSK9 protein(Met1-Gln692), His-tagged | +Inquiry |
PCSK9-1588C | Recombinant Cynomolgus PCSK9 protein, His-tagged | +Inquiry |
PCSK9-414R | Recombinant Rhesus macaque PCSK9 Protein, His-tagged | +Inquiry |
PCSK9-486R | Recombinant Rhesus PCSK9 Protein (Met1-Gln692), MIgG1 Fc-tagged | +Inquiry |
◆ Lysates | ||
PCSK9-2775RCL | Recombinant Rhesus PCSK9 cell lysate | +Inquiry |
PCSK9-2306RCL | Recombinant Rat PCSK9 cell lysate | +Inquiry |
PCSK9-2564MCL | Recombinant Mouse PCSK9 cell lysate | +Inquiry |
◆ Assay kits | ||
Kit-1806 | PCSK9(D374T)-LDLR TR-FRET Assay Kit | +Inquiry |
Kit-1808 | PCSK9-LDLR TR-FRET Assay Kit | +Inquiry |
Kit-1807 | PCSK9[Biotinylated]-LDLR Binding Assay Kit | +Inquiry |
Kit-0665 | PCSK9-BIRC2 in vitro Binding Assay Kit | +Inquiry |
Related Gene
Not For Human Consumption!
Inquiry
- Reviews
- Q&As
Customer Reviews (3)
Write a reviewIn immunological experiments, it was found that it had good antigenicity and could induce target immune responses.
It promoted cell growth and proliferation.
High catalytic efficiency.
Q&As (6)
Ask a questionYes, some studies suggest that mutations in the PCSK9 protein gene may increase the risk of cardiovascular disease. For example, some PCSK9 mutations can cause their dysfunction, resulting in hypercholesterolemia and cardiovascular disease.
PCSK9 protein is combined with immune adjuvants to make a vaccine, or mutated PCSK9 protein to induce an immune response to it, inhibit PCSK9 expression in vivo, increase LDLR levels and reduce serum cholesterol levels.
This protein may have a regulatory effect on weight and obesity, and it is associated with glucose and endocannabinin homeostasis studies have linked PCSK9 to the development of obesity and diabetes.
Several new anti-PCSK9 drugs are already being studied and developed, including oral drugs and gene chromosome therapies, and some drugs have advanced to early stages of clinical trials, providing new options for the treatment of PCSK9 proteins.
Currently on the market to inhibit PCSK9 protein drugs include alirocumab and evolocumab.
PCSK9 protein can degrade LDLR protein, so its overexpression will lead to a decrease in LDLR's ability to be cleared, leading to hypercholesterolemia.
Ask a Question for All PCSK9 Products
Required fields are marked with *
My Review for All PCSK9 Products
Required fields are marked with *
Inquiry Basket